Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
SpringWorks Therapeutics is a commercial-stage biopharmaceutical company focused on acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from severe rare diseases and cancer. They employ a precision medicine approach, targeting therapies to genetically defined patient populations. Their lead product, OGSIVEOâ„¢ (nirogacestat), is approved for treating adults with desmoid tumors. The company's pipeline includes other programs in various stages of clinical development for oncology and rare diseases.
The Stamford headquarters serves as the central hub for corporate leadership, strategic planning, research and development oversight, clinical operations management, and commercialization efforts.
The headquarters is located in a modern office building, likely equipped with facilities that support a dynamic biopharmaceutical company, fostering collaboration and innovation. Specific architectural highlights are not widely publicized.
The work culture at SpringWorks Therapeutics is characterized by a strong emphasis on scientific excellence, patient-centricity, urgency, and collaboration. As a growing biopharma, it likely fosters an innovative and results-driven environment.
The headquarters' location in Stamford provides access to a rich talent pool from the pharmaceutical and biotech industries in the Northeast, as well as proximity to financial markets and key partners.
SpringWorks Therapeutics currently has a primary operational focus in the United States for its commercial activities and corporate functions. However, its clinical development programs are global, with trial sites often located across North America, Europe, and potentially other regions to ensure diverse patient enrollment and to support future international regulatory submissions and market access.
100 Washington Blvd, Suite 700
Stamford
CT
USA
Address: Specific address not publicly listed for research facility.
To tap into the specialized talent pool and research collaborations available in one of the leading U.S. biotech hubs, focusing on advancing early-pipeline assets.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, SpringWorks Therapeutics' leadership includes:
SpringWorks Therapeutics has been backed by several prominent investors over the years, including:
Over the past 12-18 months, SpringWorks Therapeutics has strengthened its executive team with key appointments like a new CFO and CCO, reflecting its transition into a commercial-stage company. No major high-profile executive exits have been publicly announced during this period.
Discover the tools SpringWorks Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
SpringWorks Therapeutics most likely utilizes common corporate email formats. The predominant patterns are typically [first_initial][last]@[companydomain.com] or [first].[last]@[companydomain.com].
flast@springworkstx.com
Format
jsmith@springworkstx.com
Example
90%
Success rate
SpringWorks Therapeutics Press Release • May 9, 2024
SpringWorks Therapeutics announced its Q1 2024 financial results, highlighting net product revenue from OGSIVEOâ„¢ sales, progress in its clinical pipeline, and upcoming milestones. The company reported $20.3 million in OGSIVEOâ„¢ net product revenue....more
SpringWorks Therapeutics Press Release • November 27, 2023
The U.S. Food and Drug Administration (FDA) approved OGSIVEOâ„¢ (nirogacestat), an oral gamma-secretase inhibitor, for adult patients with progressing desmoid tumors requiring systemic treatment. This is the first approved therapy for desmoid tumors....more
SpringWorks Therapeutics Press Release • April 3, 2024
The pivotal Phase 3 DeFiANT trial results for OGSIVEOâ„¢ (nirogacestat) in patients with desmoid tumors were published in The New England Journal of Medicine, detailing the efficacy and safety data that supported its FDA approval....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including SpringWorks Therapeutics, are just a search away.